Radiofrequency Ablation of Unifocal Papillary Thyroid Microcarcinoma With BRAF V600E Mutation
Authors' conclusion
RFA is effective and safe in treating unifocal PTMCs with BRAF V600E mutation, especially when surgery is not feasible or refused by patients who are unwilling to continue active surveillance.
Study context
- Population
- Patients with unifocal BRAF V600E mutation-positive papillary thyroid microcarcinoma (PTMC) treated January 2020–December 2021; mean maximum tumor diameter 5.8 ± 1.7 mm (range, 2.5–10.0 mm)
- Participants
- 60 papillary thyroid microcarcinomas (PTMCs)
- Outcome
- Efficacy of RFA
- Follow-up
- Last
Methodological detailssingle-arm, ultrasound (US)-guided percutaneous
- Single-arm
- US-guided percutaneous
Main finding
As reported in the abstract
Nodules completely disappeared
42
70.0%
Ablation zones with fissure-like changes
18
30.0%
Local recurrence or cervical lymph node metastasis (LNM)
0
Observational data: associations, not effects.
Further findings
- Ablation zone sizes increased immediately after radiofrequency ablation (RFA) vs tumors before treatment
- At 1 month, ablation zone sizes smaller than immediately after RFA
Safety
- Voice change (only major complication)
- 1.7%
Original publication
Radiofrequency Ablation of Unifocal Papillary Thyroid Microcarcinoma With BRAF V600E Mutation. J Clin Endocrinol Metab. Published 23 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →